No profile data available.
Oramed Pharmaceuticals Inc. (ORMP) is a healthcare company in the blood sugar management drugs industry, based in New York, United States.
It reported revenue of $2.00 million for fiscal year 2025, and net income of $64.05 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $177.21 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes.
Oramed Pharmaceuticals reported $2.00 million in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$177.21 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood sugar management drugs) include Eli Lilly and Company (LLY), Novo Nordisk A/S (NVO), Biomea Fusion, Inc. (BMEA), Vicapsys Life Sciences, Inc. (VICP).